Literature DB >> 9218575

Cytokine-deficient CD8+ Tc1 cells induced by IL-4: retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells.

S Sad1, L Li, T R Mosmann.   

Abstract

After antigenic stimulation, naive CD8+ T cells differentiate into cytotoxic Tc1 cells secreting the cytokines IL-2, IFN-gamma, and TNF, which aid their proliferation and effector functions. We have previously shown that IL-4 acts directly on differentiated Tc1 cells to impair subsequent Con A-induced IL-2 production. As IL-4 may be produced in the vicinity of Tc1 cells during normal immune responses, we have further analyzed the short and long term functions of IL-4-treated Tc1 cells. We now show that these cells also have a defect in the synthesis of IFN-gamma, TNF, and IL-10 in response to antigenic stimulation. IL-2 synthesis was the most sensitive, as stimulation of IL-4-treated Tc1 cells with higher numbers of APCs partially restored IFN-gamma, TNF, and IL-10, but not IL-2, synthesis. Injection of allo-specific Tc1 cells into mice expressing the target Ag revealed reduced cytokine synthesis in vivo by IL-4-treated Tc1 cells. Loss of cytokine synthesis did not impair the short term effector functions of Tc1 cells, as they induced adoptively transferred delayed type hypersensitivity in recipient mice and retained both perforin- and Fas-dependent cytolytic mechanisms in vitro. Long term coculture of tumor targets and tumor-specific Tc1 cells indicated that normal Tc1 cells proliferated and killed tumor cells, whereas IL-4-treated Tc1 cells failed to proliferate and hence were unable to curtail the proliferation of tumor cells. These results suggest that IL-4 synthesis in vivo would not affect immediate effector functions of differentiated Tc1 cells, but would compromise immunity by reducing their long term functional capability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218575

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  CD4+ T cell-independent DNA vaccination against opportunistic infections.

Authors:  Mingquan Zheng; Alistair J Ramsay; Myles B Robichaux; Corrine Kliment; Christopher Crowe; Rekha R Rapaka; Chad Steele; Florencia McAllister; Judd E Shellito; Luis Marrero; Paul Schwarzenberger; Qiu Zhong; Jay K Kolls
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

2.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit.

Authors:  Kotaro Sasaki; Angela D Pardee; Hideho Okada; Walter J Storkus
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

4.  Anti-inflammatory cytokines directly inhibit innate but not adaptive CD8+ T cell functions.

Authors:  Bailey E Freeman; Christine Meyer; Mark K Slifka
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

Review 5.  Role of Different Subpopulations of CD8+ T Cells during HIV Exposure and Infection.

Authors:  Sandra Milena Gonzalez; Natalia Andrea Taborda; María Teresa Rugeles
Journal:  Front Immunol       Date:  2017-08-07       Impact factor: 7.561

6.  An oral recombinant Salmonella enterica serovar Typhimurium mutant elicits systemic antigen-specific CD8+ T cell cytokine responses in mice.

Authors:  Nyasha Chin'ombe; William R Bourn; Anna-Lise Williamson; Enid G Shephard
Journal:  Gut Pathog       Date:  2009-04-29       Impact factor: 4.181

7.  Role of TH17 Responses in Increasing Herpetic Keratitis in the Eyes of Mice Infected with HSV-1.

Authors:  Satoshi Hirose; Ujjaldeep Jaggi; Shaohui Wang; Kati Tormanen; Yoshiko Nagaoka; Makoto Katsumata; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.